Exendin-4 improves glucose metabolism in insulin-resistant cells by upregulating the phosphorylative AMPK

Huaijie Wang1#, Han Su1,3#, Jian Li1,3, Shengyao Ma1, Na Li1,4, Bin Jiang1, Meijia Zhang2, Lianguang Huo1, Gong Dai1, Zhiquan Gao1*, Xiaoyun Yang1*, Meihua qu1,2*

1Key Laboratory of Applied Pharmacology, Weifang Medical University, Weifang, Shandong 261053, China; 2Weifang Second People’s Hospital, Weifang Respiratory Disease Hospital, Weifang, Shandong 261031, China; 3Department of Pharmacy, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, China; 4Medical Center, Ohio State University, Columbus, OH 43210, USA

#These authors contributed equally to this study
*Corresponding authors: Meihua Qu, Weifang Medical University, 7166 Baotong West Street, Weifang, 261053 China. E-mail: qumeihua2016@163.com; Weifang Second People’s Hospital, 7 Yuanxiao Street, Weifang, 261041 China; Xiaoyun Yang, Weifang Medical University, 7166 Baotong West Street, Weifang, 261053 China, E-mail: xiaoyuny1118@163.com; Zhiqin Gao, School of Bioscience and Technology, Weifang Medical University, 7166 Baotong West Street, Weifang, 261053 China. E-mail: zhiqingao2013@163.com

Received October 28, 2019; Accepted December 13, 2019

Glucagon-like peptide-1 (GLP-1) is a peptide with multiple functions in regulating blood glucose with the mechanism still not thoroughly understood. AMP-activated protein kinase (AMPK) plays an important role in glucose and energy homeostasis, especially in type 2 diabetes mellitus (T2DM) pathophysiology. This study explores GLP-1 analogue exendin-4 (Ex-4) regulating glucose balance by activating AMPK and regulation gluconeogenesis in insulin-resistant cell model (IR/HepG2). IR/HepG2 cells were treated with Ex-4, AMPK activator or Ex-4 pretreated with AMPK inhibitor Compound C. The change of cell morphology, glucose consumption and lipid content in IR/HepG2 cells were examined. The expression of AMPK and p-AMPK in IR/HepG2 treated by Ex-4 were determined by Western blot and immunohistochemistry (IHC) assay. Key enzymes of glucose metabolism, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase) in IR/HepG2 cells treated by Ex-4 were detected by Western blot, immunohistochemistry and qRT-PCR. The results showed that Ex-4 treatment increased the expression of p-AMPK and reduced the expression of G-6-Pase and PEPCK in IR/HepG2 cells. Pretreatment with AMPK inhibitor Compound C counteracts the effect of Ex-4. These findings suggest that Ex-4 fulfilled it glucose regulation effect by phosphorylation of AMPK and decreased the expression of enzymes involving gluconeogenesis.

Key Words: Insulin resistance; IR/HepG2; GLP-1; Exendin-4; AMPK

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is commonly caused by the abnormal secretion of insulin or insulin resistance (IR).1,2 Insulin resistance is a process in which peripheral tissues, particularly the liver, muscle and fat, become resistant to insulin, which is a primary factor underlying the etiology of T2DM.3 Therefore, developing antidiabetic drugs that exert effects on insulin sensitivity is critical for the cure of T2DM. AMP-activated protein kinase (AMPK) is a cellular nutrient sensor that affects cellular energy homeostasis.4,5 Once activated, AMPK plays a different role in cells by turning off energy-utilizing pathways and turning on energy-generating pathways.6 Studies have shown that AMPK increases insulin sensitivity in certain cells and improves metabolic milieu that may lead to reducing the risk of T2DM.7 Glucagon-like peptide-1 (GLP-1) is an incretin secreted by L-cells...
of the small intestine, which promotes the β cells of the pancreas to secrete insulin after food intake.\textsuperscript{4,5} GLP-1 analogue has become a second-line therapeutic drug for 2DM treatment.\textsuperscript{10,11} GLP-1 analogue, Exendin-4 (Ex-4), has been used in clinical treatment of type 2 diabetes mellitus (T2DM).\textsuperscript{12,13}

Recent studies have found that GLP-1 promotes the phosphorylation of AMPK in hepatocytes and reduces the glucose content of hepatocytes in diabetic mice.\textsuperscript{13} Other studies showed that exenatide had direct protective effects on endothelial cells through the AMPK/Akt pathway in a GLP-1 receptor-dependent manner.\textsuperscript{14,15} However, the interaction of GLP-1 and AMPK in the treatment of diabetes is not clear. In this study, we explored the mechanism of GLP-1 analogue Exendin-4 (Ex-4) activated AMPK and decreased the key enzymes involving glucogenesis in insulin-resistant (IR) HepG2 cells.

**MATERIALS AND METHODS**

**Reagents**

Dulbecco’s Modified Eagle’s Medium (DMEM) supplements were purchased from Hyclone (UT, USA). Fetal bovine serum (FBS), bovine insulin was purchased from Solarbio Life Science (Beijing, China). Rabbit anti-AMPK and Rabbit anti-p-AMPK were obtained from Cell Signaling Technology (MA, USA). Rabbit anti-PEPCK and rabbit anti-glucose-6-phosphatase (G-6-Pase) were obtained from Abcam (MA, USA). Rabbit anti-GAPDH was obtained from Cell Signaling Technology (MA, USA). Rabbit anti-AMPK and Rabbit anti-p-AMPK were obtained from Med Chem Express (MCE, USA). The glucose oxidase-peroxidase (GOD-POD) kit was obtained from Applygen Technologies Inc (Beijing, China).

**Establishing the IR/HepG2 cell model**

HepG2 cells were obtained from the Chinese Academy of Sciences Cell Bank (Shanghai, China), and cultured in high glucose DMEM with 10% FBS, 100 IU/mL penicillin and 100 mg/mL streptomycin in an incubator with humidified atmosphere and 5% CO\textsubscript{2} at 37°C. HepG2 cells were seeded in 96-well plate at 5×10\textsuperscript{4} cells/well in high glucose DMEM with 2% FBS and cultured for 24 h to reach 80% confluence. After 12 h of serum starvation, the cells were stimulated with various concentrations (10\textsuperscript{5}, 10\textsuperscript{4}, 10\textsuperscript{3} or 10\textsuperscript{2} mol/L) of insulin for 12, 24, 36 or 48 h. The glucose consumption in cell supernatant was determined by glucose GOD-POD kit. It was found that IR/HepG2 cell model was established using the stimulation of insulin at 10\textsuperscript{3} mol/L for 36 h.

**IR/HepG2 cell treatment**

IR/HepG2 cells were incubated in serum-free DMEM to reach 70% confluence and then treated with Ex-4 (100nM), AICAR (1mM) or Compound C as described above, fixed with 4% paraformaldehyde for 30 min. After incubating in TBST containing 3% bovine serum albumin (BSA) for 1 h at room temperature, the cells were incubated overnight at 4°C with a primary rabbit anti-p-AMPK (1:200), rabbit anti-PEPCK (1:100) and rabbit anti-G-6-Pase (1:100) diluted in TBST containing 5% skim milk. Cells were washed with TBST 3 times for 10 min each and incubated for 1 h with HRP-linked goat anti-rabbit IgG (1:500) at room temperature. Cells were washed with TBST 3 times for 10 min before diaminobenzidine (DAB) was added. The localization and expression of p-AMPK, G-6-Pase and PEPCK were observed under a Nikon Eclipse Ti- SR microscope (Tokyo, Japan).

**Determination of the glucose consumption by oxidase-peroxidase Assay**

Total RNA of HepG2 and IR/HepG2 cells was extracted by TRIzol and dissolved in DEPC-treated distilled water. Total RNA (1μg) was reversely transcribed into cDNA using a Toyobo Rever Tra Ace qPCR-RT kit. The primers were designed by prism 5.0 software and the sequences were listed as follows (5′-3′): AMPK: F-CTCACCTCTCTCCAAGTATT and R-TCGATGGGCTTA-TACAGG; PEPCK: F-TGCATGAAGGTCGACCA and R-CA-GAATGGAGGCAATT ; G-6-Pase: F-TGCTTTCTTTCCACT-CAGGCA and R-TGCTTTCTTTCCACTGCA; GAPDH: F-T-CAACGACACTTTGTCAAGCTCA and R-CTGGTGGTCCA-GGTTTCCTTACT. qRT-PCR of these genes was performed using an SYBR Green fluorescent PCR kit. The PCR program was 95°C for 10 min and 40 cycles at 95°C for 5 s, 55°C for 10 s, and 72°C for 15 s, following 7 min at 72°C. All samples were analyzed using 2\textsuperscript{-ΔΔCt} method in parallel for GAPDH expression.

**Western blot analysis**

Drugs treated HepG2 and IR/HepG2 cells were harvested and lysed in lysis buffer. 40 μg total protein was loaded in each well and run in 10% SDS-polyacrylamide gels at 110 V for 2 h. The proteins were transferred to PVDF membrane at 300 mA for 100 min at 4°C. After incubation in blocking solution (5% skim milk in TBST), membranes were incubated with antibodies overnight at 4°C. The
antibodies used were AMPK (1:1000), p-AMPK (1:1000), PEPCK (1:400), G-6-Pase (1:500) and GADPH (1:1000). Membranes were washed 3 times for 10 min by TBST, and incubated with IRDye 800CW-conjugated goat anti-rabbit antibody (1:10000). Protein bands were visualized by an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, USA), and the intensity of each band was quantified using the Image J software.

Statistical analysis

The data were expressed as the mean ± SD. SPSS software (SPSS Inc., Chicago, USA) was used for graphical representation and statistical analysis. One way ANOVA with Tukey’s and S-N-K post hoc test was employed for multiple comparisons. Values of P<0.05 were considered statistically significant.

RESULTS

Establishment of the insulin-resistant IR/HepG2 cell model

Insulin resistant IR/HepG2 cell model was successfully established by treating HepG2 cells with high glucose and high concentration of insulin. The established insulin-resistant cells were evaluated by glucose consumption assay. The results showed that HepG2 cells treated with 10⁻⁷mol/L insulin for 36 h significantly reduced the glucose consumption (Table 1), indicating the successful establishment of insulin resistant cell model. The glucose consumption decreased in IR/HepG2 cells compared to HepG2 cells (P<0.001) (Fig. 1A). The expression of G-6-Pase and PEPCK were used to evaluate glucose metabolism in IR/HepG2 cells. Western blot results showed G-6-Pase and PEPCK expression significantly increased in IR/HepG2 cells compared to control HepG2 cells (Fig. 1B). Figure 1C and figure 1D showed G-6-Pase and PEPCK expression in IR/HepG2 cells increased 1.5 and 2fold comparing to HepG2 cells calculated by Image J software, respectively. Oil red O staining was performed to observe the changing of fat metabolism in IR/HepG2 cells. The results showed increased fat droplets accumulated in IR/HepG2 cells compared to HepG2 cells (Fig. 1E).

Ex-4 increased AMPK phosphorylation in IR/HepG2 cells

To explore whether Ex-4 affected glucose metabolism by activating AMPK in insulin-resistant HepG2 cells, the expression of AMPK and phospho-AMPK were examined by Western blotting and IHC. AICAR is an activator of AMPK and is used as a positive control, while Compound C is commonly used as an inhibitor of AMPK and is used as a negative control in this study. Insulin resistant HepG2 cells were treated by Ex-4, AMPK activator AICAR, and Ex-4 pretreated by AMPK inhibitor Compound C, respectively. Western blot results showed Ex-4 and AMPK activator AICAR significantly increased the phosphorylation of AMPK, no significantly changing of AMPK expression was observed. Compound C pretreating attenuated increasing phosphorylation of AMPK effect by Ex-4 (Fig. 2A and Fig 2B). These data indicated that Ex-4 increased the protein phosphorylation of AMPK, but Ex-4 has no effect the protein phosphorylation of AMPK pretreated with Compound C. Immunocytochemistry showed similar expression trends in comparison of these four groups as Western blot (Figure 2C). It demonstrated that the role of GLP-1 in glucose metabolism is associated with AMPK. The protein of G-6-Pase and PEPCK is dramatically reduced after using Ex-4 and Ex-4 can improve glucose metabolism in IR/HepG2 cells. Our results demonstrated that Ex-4-AMPK signaling pathway is important in improving glucose metabolism.

Ex-4 improved glucose metabolism and decreased the expression of G-6-Pase and PEPCK in IR/HepG2 cells

The glucose consumption of IR/HepG2 cells treated by Ex-4, AMPK activator AICAR, and Ex-4 pretreated by Compound C was evaluated using the GOD-POD assay kit. The results showed that glucose consumption significantly increased in Ex-4 and AICAR treated IR/HepG2 cells. Pretreating with Compound C attenuated the increased glucose consumption by Ex-4 (Fig. 3A).

In order to understand the molecular mechanism of Ex-4 in glucose metabolism regulation, G-6-Pase and PEPCK expression in different agents treated IR/HepG2 cells by qRT-PCR and Western blot. qRT-PCR data showed that Ex-4 and AICAR significantly reduced the mRNA expression of G-6-Pase and PEPCK in IR/HepG2 cells. Pretreated by compound C reversed Ex-4 function in decreasing G-6-Pase and PEPCK mRNA expression (Fig. 3B-C). Figure 3D-F showed the Western blot results of the four
Exendin-4 improves glucose metabolism by upregulating AMPK phosphorylation

groups. Figure 3G showed the IHC results also indicated that Ex-4 decreased the expression of G-6-Pase and PEPCK in IR/HepG2 cells. Blocking AMPK by Compound C reversed the effect of Ex-4 (Fig. 3G).

DISCUSSION

Insulin resistance is a physiologic state of a declined response to insulin, which is mainly triggered by longterm hyperglycaemia and the main reason of T2DM. Insulin resistance is characterized by the inhibition of glucose uptake in insulin-sensitive tissues, such as liver, muscle and adipose tissue. The liver plays an important role in regulating energy balance and maintaining glucose homeostasis, and it is also the key organ in T2DM pathophysiology. HepG2 cells originate from liver cells and retain many characteristics of hepatocytes. In this study, HepG2 cells were induced to insulin-resistance HepG2 cells (IR/HepG2) by high glucose and high insulin treatment. Hepatic gluconeogenesis is a crucial process regulating glucose metabolism. It has been reported that increased hepatic gluconeogenesis is mainly caused by overexpression of two key gluconeogenetic enzymes, G-6-Pase and PEPCK. PEPCK and G-6-Pase expression in IR/HepG2 cells treated by Ex-4 or other reagents were also evaluated in this study.

Glucagon-like peptide-1 (GLP-1) receptor agonists and DDPV inhibitors are new drugs in T2DM treatment. It is reported that GLP-1 receptor agonist, the novel antidiabetic drug (Ex-4), can improve lipid deposition in hepatocytes.

Studies indicated that activation of the central nerve system GLP-1 receptor improves T2DM via glucose metabolism dependent inhibition of central nerve system AMPK. AMPK activation accelerate fatty acid oxidation and glucose uptake, suppresses triglycerides production in skeletal muscle, which is necessary for the body to maintain the balance of blood glucose. In this study, AMPK and p-AMPK were examined to understand whether Ex-4 improves glucose metabolism by increasing phosphorylation of AMPK. It was found that Ex-4 ameliorated the hepatic glucose metabolism by activating AMPK activity and decreasing the key enzymes involving gluconeogenesis.

Taken together, our results indicate that Ex-4 activating AMPK is the main mechanism in improving insulin resistance. Targeting Ex-4/AMPK signaling pathway, especially AMPK activating, could be promising in the treatment of T2DM.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81871892, 31671208, 81471048, 81500798, and 81503108), Shandong Province Natural Science Foundation (ZR2015HL128) and Technology Development Plan of Weifang (2018YX027).

Author contributions

Meihua Qu, Zhiqin Gao and Xiaoyun Yang designed the project; Meihua Qu, Zhiqin Gao, Huijie Wang and Han Su write the paper; Huijie Wang, Han Su, Jian Li, Shengyao Ma, Na Li, Bin Jiang, Meijia Zhang, Lianguang Huo, Gong Dai, Xiaoyun Yang, performed the experiment and data analysis.

Conflicts of Interest

The authors declare no potential conflicts of interest associated with this research.
REFERENCES


